BR112015014270A2 - co-diferenciação de monócitos a partir de doadores alogênicos - Google Patents
co-diferenciação de monócitos a partir de doadores alogênicosInfo
- Publication number
- BR112015014270A2 BR112015014270A2 BR112015014270A BR112015014270A BR112015014270A2 BR 112015014270 A2 BR112015014270 A2 BR 112015014270A2 BR 112015014270 A BR112015014270 A BR 112015014270A BR 112015014270 A BR112015014270 A BR 112015014270A BR 112015014270 A2 BR112015014270 A2 BR 112015014270A2
- Authority
- BR
- Brazil
- Prior art keywords
- allogeneic
- differentiation
- donors
- monocytes
- monocyte
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title abstract 9
- 210000001616 monocyte Anatomy 0.000 title abstract 4
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo da patente de invenção para: co-diferenciação de monócitos a partir de doadores alogênicos. a presente invenção descreve um método de produção de células dendríticas imaturas não esgotadas (dcs) proveniente de dois doadores alogênicos diferentes. no método, uma mistura de leucócitos alogênicos, em que os leucócitos alogênicos foram obtidos a partir de pelo menos dois doadores alogênicas diferentes é fornecido. subsequentemente, monócitos alogênicos são isolados a partir da mistura de leucócitos alogênicos. depois disso, as dcs imaturas não esgotadas são geradas a partir dos referidos monócitos alogénicos isolados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197687.2 | 2012-12-18 | ||
| EP12197687 | 2012-12-18 | ||
| PCT/EP2013/077139 WO2014096033A1 (en) | 2012-12-18 | 2013-12-18 | Co-differentiation of monocytes from allogeneic donors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015014270A2 true BR112015014270A2 (pt) | 2015-11-03 |
| BR112015014270B1 BR112015014270B1 (pt) | 2018-12-04 |
Family
ID=47427250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015014270-2A BR112015014270B1 (pt) | 2012-12-18 | 2013-12-18 | co-diferenciação de monócitos a partir de doadores alogênicos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9714413B2 (pt) |
| EP (2) | EP2913394B1 (pt) |
| JP (1) | JP6529439B2 (pt) |
| KR (1) | KR102148051B1 (pt) |
| CN (2) | CN105452449B (pt) |
| AU (1) | AU2013360793B2 (pt) |
| BR (1) | BR112015014270B1 (pt) |
| CA (1) | CA2895280C (pt) |
| DK (2) | DK2913394T3 (pt) |
| ES (2) | ES2591230T3 (pt) |
| HU (2) | HUE028895T2 (pt) |
| MX (1) | MX357491B (pt) |
| PL (2) | PL2913394T3 (pt) |
| RU (1) | RU2668816C2 (pt) |
| SI (2) | SI2913394T1 (pt) |
| WO (1) | WO2014096033A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3460052T3 (pl) | 2017-09-20 | 2020-05-18 | Immunicum Ab | Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu |
| CA3087418A1 (en) * | 2018-01-18 | 2019-07-25 | University Of South Florida | Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases |
| CN108660125A (zh) * | 2018-05-14 | 2018-10-16 | 武汉博百欧生物科技有限公司 | 一种从人体输血废弃物中提取中性粒细胞嗜天青颗粒的方法 |
| WO2020154424A1 (en) * | 2019-01-22 | 2020-07-30 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051617A1 (en) * | 2000-01-11 | 2001-07-19 | Maxygen, Inc. | Monocyte-derived dendritic cell subsets |
| AU2002326463A1 (en) | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| SI1509244T1 (sl) | 2002-06-06 | 2011-11-30 | Immunicum An | Nov postopek in spojina za izdelavo celične alogenične vakcine |
| KR100585456B1 (ko) * | 2003-09-30 | 2006-06-07 | 국립암센터 | 동종 종양-관련 항원이 탑재된 수지상세포, 이의 제조방법및 이를 유효성분으로 하는 암 치료용 백신 조성물 |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| CA2632263C (en) * | 2005-12-08 | 2022-01-11 | Northwest Biotherapeutics, Inc. | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
| EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| US9034317B2 (en) * | 2010-02-10 | 2015-05-19 | Immunicum Ab | Composition for inhibiting tumor cell proliferation |
| WO2012140130A1 (en) * | 2011-04-13 | 2012-10-18 | Immunicum Ab | Method for proliferation of antigen-specific t cells |
| JP2014511704A (ja) * | 2011-04-13 | 2014-05-19 | イミュニカム・エイビイ | Ｔ細胞のプライミングのための方法 |
-
2013
- 2013-12-18 ES ES15161369.2T patent/ES2591230T3/es active Active
- 2013-12-18 KR KR1020157015766A patent/KR102148051B1/ko active IP Right Grant
- 2013-12-18 RU RU2015119164A patent/RU2668816C2/ru active
- 2013-12-18 HU HUE15161369A patent/HUE028895T2/en unknown
- 2013-12-18 EP EP15161369.2A patent/EP2913394B1/en active Active
- 2013-12-18 CN CN201380066722.0A patent/CN105452449B/zh active Active
- 2013-12-18 DK DK15161369.2T patent/DK2913394T3/en active
- 2013-12-18 SI SI201330281A patent/SI2913394T1/sl unknown
- 2013-12-18 CN CN201910284719.5A patent/CN110042081B/zh active Active
- 2013-12-18 AU AU2013360793A patent/AU2013360793B2/en active Active
- 2013-12-18 US US14/653,184 patent/US9714413B2/en active Active
- 2013-12-18 JP JP2015547082A patent/JP6529439B2/ja active Active
- 2013-12-18 CA CA2895280A patent/CA2895280C/en active Active
- 2013-12-18 WO PCT/EP2013/077139 patent/WO2014096033A1/en active Application Filing
- 2013-12-18 BR BR112015014270-2A patent/BR112015014270B1/pt not_active IP Right Cessation
- 2013-12-18 DK DK13814106.4T patent/DK2788474T3/en active
- 2013-12-18 PL PL15161369.2T patent/PL2913394T3/pl unknown
- 2013-12-18 EP EP13814106.4A patent/EP2788474B1/en active Active
- 2013-12-18 ES ES13814106.4T patent/ES2548229T3/es active Active
- 2013-12-18 MX MX2015007800A patent/MX357491B/es active IP Right Grant
- 2013-12-18 PL PL13814106T patent/PL2788474T3/pl unknown
- 2013-12-18 HU HUE13814106A patent/HUE027619T2/en unknown
- 2013-12-18 SI SI201330066T patent/SI2788474T1/sl unknown
-
2017
- 2017-06-15 US US15/623,530 patent/US10626371B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| BR112016015496A2 (pt) | composição e processo para a produção da composição | |
| EA202092987A3 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| BR112013029834A8 (pt) | vacinas individualizadas para câncer | |
| EA201590868A1 (ru) | Противовирусные соединения | |
| MX2013009545A (es) | Aparato y metodo para aislar leucocitos y celulas tumorales por filtracion. | |
| UA114087C2 (xx) | Похідні піридину | |
| EA201790963A1 (ru) | Противовирусные соединения | |
| MX2021008755A (es) | Un anticuerpo anti-tau para usarse al tratar una tauopatia. | |
| CL2013003259A1 (es) | Proceso para deshidratar una suspension de celulosa microfibrilada, el cual comprende: proporcionar una suspensión de celulosa microfibrilada y líquido, someter la suspensión a un campo eléctrico induciendo el liquido de la suspension a fluir, y separar el líquido de la celulosa microfibrilada. | |
| BR112016029333A2 (pt) | síntese de compostos de carbamoilpiridona policíclico | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| BR112015012987A2 (pt) | composições compreendendo anticorpos anti-cd38 e lenalidomida | |
| EA201890333A1 (ru) | Противовирусные соединения | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| BR112013027847A8 (pt) | Componente de catalisador de titânio sólido para a produção de uma poliolefina, método de fabricar o mesmo, e, sistema de catalisador para a polimerização de uma olefina | |
| EA201590887A1 (ru) | Композиция | |
| MX2016007128A (es) | Compuestos del receptor 6 de quimiocina (ccr6). | |
| BR112015021189A2 (pt) | métodos de banco de células de alta densidade | |
| BR112015028395B8 (pt) | Método, sistema e montagem guia para separação de conjuntos de vísceras eviscerados de aves abatidas | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| BR112015014270A2 (pt) | co-diferenciação de monócitos a partir de doadores alogênicos | |
| BR112014017841A8 (pt) | Processo para a preparação de uma composição condutora utilizando um masterbatch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |